Brief: Tempest Therapeutics President Tom Dubensky Resigns
07/09/2023 21:47
Sept 7 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST THERAPEUTICS - ON SEPT 2, 2023, TOM DUBENSKY
RESIGNED
FROM ROLE AS PRESIDENT, MEMBER OF BOARD OF CO
* TEMPEST THERAPEUTICS - TOM DUBENSKY WILL TRANSITION TO AN
ADVISOR ROLE ON SEPTEMBER 15, 2023
* TEMPEST THERAPEUTICS - BOARD WILL APPOINT STEPHEN BRADY,
CO'S
CHIEF EXECUTIVE OFFICER, AS PRESIDENT AND CEO EFFECTIVE AS OF
SEPT 15, 2023
Source text for Eikon: ID:
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T